TNFSF10 and lung cancer: As shown in Figure 1c,d, DEX treatment attenuated TRAIL-induced sub-G1 population and PARP cleavage in other renal cancer cells (A498), lung cancer cells (A549), and breast cancer cells (MDA-MB361).